Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...
1d
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer won its fight to buy obesity-drug maker Metsera, with an extra $1.7 billion and a little help from the Trump administration. Pfizer Inc. pulled off a comeback win, beating out Danish drug giant ...
U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war aga ...
You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted ...
Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback